Sidley’s Chad Ehrenkranz and UK-based U.S. investor Chris Yoshida consider which AI-based healthcare applications are of most interest to private equity investors, and the way in which healthcare AI lies in a desirable spot between startups and government uses of AI.
Brexit brought new challenges to the pharmaceutical industry, one of them being the special situation of Northern Ireland (NI), which, although part of the UK, remained subject to EU law under the NI Protocol. Pharmaceutical products placed on the NI market had to comply with EU law. For import purposes this created de facto an EU border between NI and the rest of the UK (namely England, Wales, and Scotland). The Windsor Framework provides a new set of arrangements to restore the smooth flow of trade within the UK.
https://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/05/GLS-Blog_Generic-imagery-12.png606833Maria Isabel Manleyhttps://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.pngMaria Isabel Manley2024-04-11 10:32:352024-06-04 15:41:26New Guidance on Parallel Import Licensing Applicable to Northern Ireland Under the Windsor Framework
On March 19, 2024, a set of 100 “Compromise Amendments” to the European Commission’s far-reaching overhaul of the EU’s rules for medicines, the Pharmaceutical Review, was adopted by the European Parliament’s ENVI Committee. Maarten Meulenbelt, Chris Boyle and Zina Chatzidimitriadou explain the main changes, associated risks, and next steps.
https://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.png00Maarten Meulenbelthttps://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.pngMaarten Meulenbelt2024-03-19 17:31:042024-03-20 11:00:24EU’s Overhaul Of Pharma Legislation Amended With Uneasy IP Compromises
Licensing deals are still relatively new in China compared to the United States and Europe. Tom Duley and Ruchun Ji explain why this means Chinese parties need to be careful about the history of terms and the choice of governing law and arbitration venue when negotiating contracts.
https://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/05/GLS-Blog_Generic-imagery-06.png606833Thomas Duleyhttps://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.pngThomas Duley2024-03-18 14:18:502024-03-29 16:54:30Chinese Parties to International Licensing Deals Should Consider How Terms Translate
Major U.S. companies are expanding their vitamins, minerals, and botanicals businesses into Europe. Diane McEnroe, Anna-Shari Melin, and Nadja Schwarz explain what to consider in relation to formulation, labelling, and marketing language when targeting this market.
https://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.png00Diane C. McEnroehttps://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.pngDiane C. McEnroe2024-03-07 11:02:442024-12-02 14:02:12Points To Check When Selling Food Supplements Outside The U.S.
Our lawyers share the top investment and regulatory trends from last month’s agenda-setting JP Morgan Health Care Conference. We expect an abundance of novel financing structures, investment focus on new disease states, and important new U.S. Food and Drug Administration (FDA) guidance.
https://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/05/GLS-Blog_Generic-imagery-10.png606833Sharon Flanaganhttps://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.pngSharon Flanagan2024-02-27 10:36:302024-02-28 10:40:45Deal Outlook for 2024 Includes GLP-1 Investments, APAC M&A, and More Spinoffs
EU member states are beginning to implement EU environmental, social, and governance (ESG) legislation into national law, meaning life sciences companies will need to look at its impact on their global supply chains, including for APIs. Michele Tagliaferri, Anna-Shari Melin, and Nadja Schwarz explain.
https://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.png00Michele Tagliaferrihttps://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.pngMichele Tagliaferri2024-02-16 14:25:472024-03-27 11:29:13Life Sciences Companies with Operations in EU Could Be Affected by ESG Law
September 30The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK
Archives
Categories
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
Private Equity Investors’ Attitudes Towards Healthcare AI Investment Opportunities
Sidley’s Chad Ehrenkranz and UK-based U.S. investor Chris Yoshida consider which AI-based healthcare applications are of most interest to private equity investors, and the way in which healthcare AI lies in a desirable spot between startups and government uses of AI.
Chad Ehrenkranz
New York, Miami
chad.ehrenkranz@sidley.com
New Guidance on Parallel Import Licensing Applicable to Northern Ireland Under the Windsor Framework
Brexit brought new challenges to the pharmaceutical industry, one of them being the special situation of Northern Ireland (NI), which, although part of the UK, remained subject to EU law under the NI Protocol. Pharmaceutical products placed on the NI market had to comply with EU law. For import purposes this created de facto an EU border between NI and the rest of the UK (namely England, Wales, and Scotland). The Windsor Framework provides a new set of arrangements to restore the smooth flow of trade within the UK.
Maria Isabel Manley
London
mmanley@sidley.com
Dr. Alexandra Anna Theochari
Trainee Solicitor
atheochari@sidley.com
EU’s Overhaul Of Pharma Legislation Amended With Uneasy IP Compromises
On March 19, 2024, a set of 100 “Compromise Amendments” to the European Commission’s far-reaching overhaul of the EU’s rules for medicines, the Pharmaceutical Review, was adopted by the European Parliament’s ENVI Committee. Maarten Meulenbelt, Chris Boyle and Zina Chatzidimitriadou explain the main changes, associated risks, and next steps.
Maarten Meulenbelt
Brussels
mmeulenbelt@sidley.com
Dr. Chris Boyle
London
cboyle@sidley.com
Zina Chatzidimitriadou
London
zchatzidimitriadou@sidley.com
Chinese Parties to International Licensing Deals Should Consider How Terms Translate
Licensing deals are still relatively new in China compared to the United States and Europe. Tom Duley and Ruchun Ji explain why this means Chinese parties need to be careful about the history of terms and the choice of governing law and arbitration venue when negotiating contracts.
Thomas Duley
San Francisco
tduley@sidley.com
Ruchun Ji
Beijing, Palo Alto
rji@sidley.com
Points To Check When Selling Food Supplements Outside The U.S.
Major U.S. companies are expanding their vitamins, minerals, and botanicals businesses into Europe. Diane McEnroe, Anna-Shari Melin, and Nadja Schwarz explain what to consider in relation to formulation, labelling, and marketing language when targeting this market.
Diane C. McEnroe
New York
dmcenroe@sidley.com
Anna-Shari Melin
Munich
amelin@sidley.com
Nadja Schwarz
Munich
nadja.schwarz@sidley.com
Deal Outlook for 2024 Includes GLP-1 Investments, APAC M&A, and More Spinoffs
Our lawyers share the top investment and regulatory trends from last month’s agenda-setting JP Morgan Health Care Conference. We expect an abundance of novel financing structures, investment focus on new disease states, and important new U.S. Food and Drug Administration (FDA) guidance.
Sharon Flanagan
San Francisco, Palo Alto
sflanagan@sidley.com
Stephen Abreu
San Francisco
sabreu@sidley.com
Robert Darwin
London
rdarwin@sidley.com
Ruchun Ji
Beijing, Palo Alto
rji@sidley.com
Carlton Fleming
San Francisco, Palo Alto
cfleming@sidley.com
Frank Rahmani
Palo Alto, San Francisco
frahmani@sidley.com
Meenakshi Datta
Chicago
mdatta@sidley.com
Emily Marden
San Francisco
emarden@sidley.com
Torrey Cope
Washington, D.C.
tcope@sidley.com
Life Sciences Companies with Operations in EU Could Be Affected by ESG Law
EU member states are beginning to implement EU environmental, social, and governance (ESG) legislation into national law, meaning life sciences companies will need to look at its impact on their global supply chains, including for APIs. Michele Tagliaferri, Anna-Shari Melin, and Nadja Schwarz explain.
Michele Tagliaferri
Brussels
mtagliaferri@sidley.com
Anna-Shari Melin
Munich
amelin@sidley.com
Nadja Schwarz
Munich
nadja.schwarz@sidley.com
Resources
Upcoming Events
Boston Life Sciences Roundtable
Women’s Life Sciences Network Event – Brussels
Swiss MedTech 2025
Staying Competitive in a Shifting Regulatory Landscape
Sidley Healthcare Investment Conference 2025
Archives
Categories